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HL 60 cell lineAbstract PPARs are ligand-regulated transcription factors and regulate expression of several gene
products. Therefore, PPARs are being studied for their possible contribution to the treatment of
cancer, atherosclerosis, inﬂammation, infertility and demyelinating diseases. Primary AML patients
were observed to have signiﬁcantly elevated PPARcmRNA expression compared to normal periph-
eral blood or bone marrow mononuclear cells. This study investigated the cytotoxic effects of ros-
iglitazone maleate, a pure PPARc agonist, in vitro in HL-60 cell line.
This study obtained results which can provide guidance for future studies. Whether the PPARy
agonist rosiglitazone maleate may provide additive effects in refractory or relapsing cases of acute
leukemia may be set as an objective for the future studies.
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PPARs are a group of nuclear receptors of the nuclear super-
family with currently 48 members identiﬁed (Chawla et al.,
2001; Berger and Moller, 2002; Barbier et al., 2002). PPAR-
a, the ﬁrst identiﬁed PPAR, was discovered in early 1980s.Because it enhanced insulin sensitivity as well as peroxisome
count in the African clawed frog known as Xenopus laevis
and in rodent hepatic tissue, it was ﬁrst named as peroxisome
proliferator. It was observed that, by increasing peroxisome
count, it elevated peroxisomal beta oxidation enzymes, i.e. acyl
CoA, and thereby fatty acid metabolism capacity in rodent
liver tissue (Green, 1995). Pharmacologically, it was demon-
strated to be related to ﬁbrates (Berger and Moller, 2002;
Pyper et al., 2010).
Nuclear receptors exert their activity by binding to DNA.
Their activity involves regulation of gene transcription. This
activity may occur in two forms: ﬁrstly, receptor initially binds
to its ligand, then they together bind to DNA or, secondly, the
receptor initially binds to DNA and then its receptor binds to
the receptor. Before reaching the nuclear receptor, the ligand
should be transported from the plasma membrane up to the
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ally with passive diffusion and carrier proteins are also utilized.
Nuclear receptors are synthesized to endoplasmic reticulum
intracellularly and they then migrate into the nucleus. Nuclear
receptors bind to DNA as a monomer or dimer. Dimer binding
may occur in two patterns, i.e. as homodimer or as heterodi-
mer (Smirnov, 2002; Germain et al., 2006; Gronemeyer
et al., 2004; Aranda and Pascual, 2001; Novac and Heinzel,
2004; Nuclear Receptors Nomenclature Committee, 1999).
PPARs are ligand-regulated transcription factors and
regulate expression of several gene products. Natural PPAR
ligands include all arachidonic acid metabolites and polyunsat-
urated fatty acids. The best known synthetic PPAR ligands are
thiazolidinediones and ﬁbrates. PPAR-c and RXR are transac-
tivated by the phosphoenolpyruvate carboxykinase (PEPCK)
gene. Adipocytes that are completely differentiated from the
ﬁbroblastic cells can be formed in PPAR-y cell cultures using
high-afﬁnity ligands. Every ligand has a primary structure con-
taining functional sites. The most important of these sites are
the DNA binding domain (DBD) and ligand binding domain
(LBD). After the receptor is activated, DBD binds to the reg-
ulator site of the DNA by two zinc-containing sites which are
called zinc ﬁngers. LBD has a large secondary protein struc-
ture involving multiple alpha helix and beta folds. Natural
and synthetic PPAR ligands activate the receptor by binding
to LBD. X-ray structure of the LBD domain of PPARy reveals
a larger ligand binding pocket than those of nuclear receptors.
Owing to this physical size, PPARs can bind multiple natural
and synthetic ligands (Sugawara et al., 2011; Kliewer et al.,
2001).
As a receptor group of the nuclear receptor superfamily, all
three PPARs are coded by different genes. PPARs activated
physiologically or pharmacologically by their ligands are also
activated by phosphorylation-modifying covalent modiﬁcation
or by interacting with a heat shock protein (HSP). The major
pathway is activation through ligand binding. This is followed
by formation of a heterodimer with retinoid X receptor, after
which they bind to speciﬁc sites on the gene DNA (Berger and
Moller, 2002). This speciﬁc DNA line has been named as ‘‘per-
oxisome proliferator response elements (PPREs)’’. When
PPAR is bound with its ligand, target genes’ transcription
either increases or decreases. Function of PPARs is regulated
via the pattern of ligand-binding site. Besides, many co-activa-
tors (SRC-1 family, CBP/p300, TRAP/DRIP complex) and
co-repressors (SMRT, N-cor) regulate PPAR functions (Wang
et al., 2012).
PPARs have critical regulator roles in lipid metabolism.
Known to be the synthetic ligands of PPARs, thiazolidinedi-
ones and ﬁbrates are still used in the treatment of diabetes mel-
litus and dyslipidemia. PPAR’s role in the treatment of cancer,
atherosclerosis, inﬂammation, infertility and demyelinating
diseases is subject of research (Kersten et al., 2000; Joseph
and Norbert, 1999; Ja¨rvinen, 2004). There are also ongoing
experimental studies on treatment of colon cancer and leuke-
mia due to their antiproliferative, apoptosis-inducing and dif-
ferentiation-enhancing activities (Lefebvre et al., 1999;
Brockman et al., 1998; Sarraf et al., 1999; Sugimura et al.,
1999; Spaner et al., 2013; Tabe et al., 2012; Wang et al., 2006).
Genetic damage, which is the basis of carcinogenesis, leads
to protooncogenes, antioncogenes and damage in one or multi-
ple genes that regulate DNA repair and apoptosis. Acute leu-
kemias develop when a single stem cell or hematopoieticprogenitor cell loses maturation and differentiation capabilities
thus exerting abnormal proliferation. In acute leukemias, dif-
ferentiation capability is blocked in leukemic blasts while pro-
liferation capacity is maintained. As a result of proliferation of
leukemic blasts and their accumulation in bone marrow, cells
that will exert normal hematopoietic function are suppressed
and bone marrow insufﬁciency develops (Beutler et al., 2001;
Hillman et al., 2005). Life expectancy in untreated acute leuke-
mia cases is maximum three months. On the other hand, with
advent of appropriate treatment methods and improved sup-
portive treatment modalities, at least one complete remission
can be achieved in about 72–90% of the patients (Estey,
2000). Relapses are observed in approximately 10–30% of
the cases and resistance to ATRA treatment usually develops
(Tallman, 1998; Warrell, 1993; Cornic and Chomienne,
1995). Several alternative mechanisms including speciﬁc bind-
ing mutations, DNA methylation, impaired telomerase regula-
tion may lead to ATRA resistance (Shao et al., 1997; Cote
et al., 2000; Di Croce et al., 2002; Pendino et al., 2002).
In primary AML cases, signiﬁcantly elevated PPARc
mRNA expression compared to normal peripheral blood or
bone marrow mononuclear cells has been observed (Konopl-
eva and Andreeff, 2002; Tsao et al., 2010).2. Purpose
A signiﬁcant progress has been achieved in the treatment of
acute leukemia, which was ﬁrst described in 1827 by the
French physician Velpeau as a febrile disease (Piller, 1993).
However, long-term disease-free survival can be achieved in
only 20–30% of the patients despite aggressive treatments.
Currently, relapses are observed with a ratio of 10–30% fol-
lowing standard remission induction and subsequent consoli-
dation treatments. Diverse approaches are being adopted to
improve treatment efﬁcacy and success. These include tumor
immunotherapy, novel chemotherapeutic agents, novel molec-
ular agents targeting the signal conduction system, drug re-
searches targeting apoptosis, studies on telomerase activity
and other experimental studies.
Given that carcinogenesis occurs as a result of multiple fac-
tors, different treatment methods for each phase are being
investigated worldwide. With known insulin sensitivity
enhancing effects, TZDs have been reported to enhance adipo-
cyte differentiation from preadipocyte (Tontonoz et al., 1994).
Studies have demonstrated that TZDs have moderate antipro-
liferative effect on many human cancer lines (prostate, breast,
colon, thyroid, lung, pituitary, pancreas, kidney, liver, blad-
der) and enhanced apoptosis (Kubota et al., 1998; Kato
et al., 2004; Ohta et al., 2001; Tsubouchi et al., 2000; Yin
et al., 2001; Heaney et al., 2003; Sasaki et al., 2001; Yang
et al., 2005; Yu et al., 2006; Yoshimura et al., 2003; Yoshizumi
et al., 2004). In addition, another experimental study revealed
that TZDs improved the efﬁcacy of imatinib treatment in Ph
chromosome-positive lymphoblastic leukemic cell line and in-
duced apoptosis (Liu et al., 2006).
Used in AML-M3 treatment, ATRA is an effective agent
against nuclear receptors. PPARc is a member of the same
receptor family. Because retinoic acid is required for PPARc
agonists’ activity, it is aimed to investigate whether rosiglitaz-
one maleate, a pure PPARc agonist, is effective on AML cell
line.
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ments and perform cytotoxicity assessment in this preliminary
study.
3. Materials and methods
3.1. Leukemic cell line and cell culture
This study investigated the cytotoxic effects of rosiglitazone
maleate, a pure PPARc agonist, in vitro in HL-60 cell line.
The cell line was obtained from Prof. Dr. Ali Ug˘ur Ural from
Cancer Research and Development Center of Gu¨lhane Mili-
tary Medical Academy (GATA).
3.2. Thawing frozen cell line
HL-60 cell line frozen with DMSO 10% was removed from
80 C and thawed at 37 C. 10–15 ml medium was added
on the cells and centrifuged at 800 rpm for 10 min. These steps
were performed as rapidly as possible to avoid toxic effects of
DMSO. The supernatant developing after centrifugation was
discarded and fresh media was introduced to the remaining cell
precipitation followed by homogenization. To eliminate toxic
material, the cells were centrifuged again at 1000 rpm for
5 min. The supernatant was discarded and similarly, fresh
media was added to cells followed by homogenization. The
cells were then transferred to ﬂasks. Passages were made to en-
sure continuity of the used cell line and to maintain viability
throughout the ongoing study.
3.3. Cell count
During cell passaging, freezing, thawing and experiments, the
cells were counted to provide an indicator of its current status.
Cell count was deﬁned as the number of cells per ml of the
medium or as the number of cells per cm3 area of the cell adhe-
sion surface. Neubauer hemocytometer was used for cell
counting.
Cells in the HL-60 cell line were counted and duplication
time with the growth curve was calculated as 72 h. In accor-
dance with the duplication time, cell passages were performed
every 72 h. During each passage, 2 · 106 cells in average were
placed in ﬂasks containing 10 ml of medium and the cells were
stained with trypan blue. The procedure continued when more
than 90% viable cells were observed. Because viable cells are
not permeable to trypan blue and the dye penetrated into dead
cells, they appear as blue. Based on these characteristics, the
cells were evaluated for viability, growth and infection using
inverted microscopy.
Aiming to demonstrate the effects of rosiglitazone maleate
on the HL-60 cell line, this study involved two phases: cell via-
bility assessment and cytotoxin assessment.
3.4. Cell viability assessment
To demonstrate cytotoxic effects of rosiglitazone maleate in
HL-60 cells, 10–20–25–30–40–50–55–60–65–70–75–80–90–
100 lM concentrations of rosiglitazone maleate were intro-
duced with double controls to each well on 24-well plates.
1 ml medium as 2–4 · 105 cells/ml was added to wells. 1 mlmedium was used as negative control. Cells on the plates were
incubated at 37 C and 95% humidity in incubators with 5%
CO2. Cell viability was assessed at 0, 24, 48, 72 and 96 h using
the Trypan blue viability test.
3.5. Cytotoxin assessment with the XTT method
The cells were analyzed spectrophotometrically at 24, 48, 72 and
96 h using the XTT solution (2,3-bis [2-methoxy-4-nitro-5-sul-
phophenyl]-2H-tetrazolium-5-carboxanilide inner salt). Re-
agents were mixed as 50 units XTT agent (Labeling reagent)/1
unit activation agent (electron coupling reagent) to prepare
XTT solution. Orange color reaction due to formazan is read
and quantiﬁed spectrophotometrically. The intensity of color
is proportional to the number of metabolically active cells.
The magnitude of the number of active cells in the wells is pro-
portional to the magnitude of mitochondrial enzymes’ activity.
HL-60 cell suspension with viability conﬁrmed by trypan
blue was delivered to 96-well plates as 1 · 106 cells/ml in each
well. A separate microplate was prepared for each measure-
ment phase (24, 48, 72 and 96 h). 100 ll cell suspension and
rosiglitazone maleate at deﬁned concentrations were added
to each well excluding controls. The total volume was made
up to 200 ll with medium and cell +200 ll reactive not con-
taining reactive was used as the negative control. Cells in
microplates were incubated at humid 37 C with 5% CO2.
One microplate at 24, 48, 72 and 96 h was collected from
groups, 50 ll XTT solution was added to each well and incu-
bated for further 4 h. At 492 nm wavelength and 630 reference
range, absorbance value for each well was read using spectro-
photometer (ELISA reader). Negative control was used as zero
absorbance.
3.6. Statistical analysis
T test was used for statistical analyses of the data obtained
from the experiments. T test results with p value below 0.05
were considered statistically signiﬁcant.
4. Results
4.1. Trypan blue viability test results
Experiments were performed at 10–20–25–30–40–50–55–60–
65–70–75–80–90–100 lM concentrations of rosiglitazone
maleate. Increasing cytotoxicity was detected at concentrations
of 70 microMolar (lM) and above.
Inhibitor concentration (IC50) dose for rosiglitazone male-
ate was 75 lM. Results of viability test performed with trypan
blue at 24, 48, 72 and 96 h in duplicate assays are shown in
Figs. 1–8.
With statistical analysis, cytotoxicity at 75 lM concentra-
tion level was signiﬁcant on each occasion compared to the
control group (p< 0.05).
4.2. XTT test cytotoxicity results
Consistent with trypan blue test results, XTT test also demon-
strated an IC50 dose resulting in 50% reduction in cell prolif-
eration at 75 lM concentration level.
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Figure 1 Viability assessment with trypan blue at 0, 24, 48, 72 and 96 h with 10, 25, 50 and 75 lM concentrations of rosiglitazone.
µM
µM
µM
µM
µM
µM
µM
µM
Figure 2 Viability assessment with trypan blue at 0, 24, 48, 72 and 96 h with 20, 25, 30, 40, 50, 60, 70 and 75 lM concentrations of
rosiglitazone.
Figure 3 Viability assessment with trypan blue at 0, 24, 48, 72 and 96 h with 50, 55, 60, 65, 70, 75, 80, 90 and 100 lM concentrations of
rosiglitazone.
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Disturbed balance between cell proliferation, apoptosis and
terminal differentiation results in neoplastic cell growth. Many
progresses in cancer treatments are being made every day. One
of these is induction of differentiation and apoptosis via the li-
gands of nuclear receptors. Gaining a better insight of nuclear
receptors and their functions will render them a target for can-
cer treatment as such knowledge improves as these molecules
play a key role in gene transcription. An example for thiswhich found established use in conventional treatments is
retinoic acid which is used in AML-M3 treatment.
PPARc agonists regulate the functions of key genes which
regulate cellular hemostasis and differentiation. Although the
underlying mechanism has not been completely elucidated,
they possess antitumor activity. It has been shown that PPARc
can be induced or is expressed in myeloid and monocytic
leukemia cell lines (Tontonoz et al., 1998; Moore et al.,
2001). Today, PPARc is also known to be expressed in liposar-
coma, colon carcinoma, gastric carcinoma, pancreas
µM
Figure 4 Viability assessment with trypan blue at 0, 24, 48, 72 and 96 h with 10 lM concentration of rosiglitazone.
µM
Figure 5 Viability assessment with trypan blue at 0, 24, 48, 72 and 96 h with 25 lM concentration of rosiglitazone.
µM
Figure 6 Viability assessment with trypan blue at 0, 24, 48, 72 and 96 h with 50 lM concentration of rosiglitazone.
µM
Figure 7 Viability assessment with trypan blue at 0, 24, 48, 72 and 96 h with 75 lM concentration of rosiglitazone.
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µM
Figure 8 Viability assessment with trypan blue at 0, 24, 48, 72 and 96 h with 100 lM concentration of rosiglitazone.
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hepatoma, prostate carcinoma, bladder carcinoma, renal cell
carcinoma, lung carcinoma, astrocytoma, glioma, neuroblas-
toma, oral squamous cell carcinoma, papillary thyroid carci-
noma, choriocarcinoma, osteosarcoma, lymphoid leukemias,
lymphoma and myeloma (Tabe et al., 2012).
PPARc activation with natural or synthetic ligands results
in inhibition of cell proliferation and/or induction of apoptosis
and differentiation. PPARc agonists target and induce cyclin-
dependent kinase inhibitors. As a result of p21 induction, a
CDK inhibitor of cip/kip family, with glitazones, arrest in
G1 phase has been observed in pancreatic tumor lines (Kawa
et al., 2002). In addition, they cause cessation of cell cycle by
directly inhibiting CDKs. With troglitazone treatment, the
cells in MCF-7 breast cancer cell lines have were to stop at
G1 phase. Previous studies have demonstrated that troglitaz-
one speciﬁcally targeted cyclin D1. Besides, when D1 overex-
pression is induced, cells were shown to avoid cell death
caused by troglitazone (Yin et al., 2001). A study by Shao
et al. demonstrated that PPARc activation prolonged the per-
iod at G1 phase in the cell cycle and that this prolongation was
associated with an increased PI3 K/Akt activity and decreased
cyclin D1 expression (Shao et al., 2002).
The studies referred to above attempted to explain antipro-
liferative effects of PPARc activation. Apart from this, it was
also shown to induce apoptosis in many studies. Exposing hu-
man breast cancer cells to troglitazone and ATRA resulted in a
decrease, which was almost unmeasurable, in bcl-2 levels,
which is considered to be the prototype of antiapoptotic genes
(Elstner et al., 1998). Similarly, more differentiated and less
malign alternations and lipid accumulation in breast epithelial
gene expression were observed with PPARc activation in
breast cancer cell line (Mueller et al., 1998).
In vivo, troglitazone was also shown to induce histopatho-
logic lipogenic differentiation of malign cells in patients with
intermediate and high-grade liposarcoma (Demetri et al.,
1999).
Following key studies in solid tumors, PPARc activation
was also studied in leukemic cell lines. Macrophages and myel-
omonocytic leukemia cells are known to express excessive
amounts of PPARc. In addition, a study by Tontonoz et al.
demonstrated increased expression of differentiation markers
such as CD11b, CD14 and CD18 following ligand activation
of PPARc in THP-1 which is a monocytic leukemia cell line
(Tontonoz et al., 1998).
PPARc expression was shown in both myeloid and lym-
phoid leukemic cell lines. PPARc activation with a naturalligand such as 15-deoxy-D12,14 – prostaglandin J2 or a synthetic
ligand such as troglitazone results in inhibition of proliferation
and induction of apoptosis. Assays demonstrated that apopto-
sis induction was mediated by caspase 3 activation. Besides,
other apoptosis-related molecules remained unchanged at hour
24 of treatment while c-myc expression was signiﬁcantly down-
regulated (Yamakawa-Karakida et al., 2002).
In their study on promyelocytic cell line HL60, Hirase et al.,
demonstrated that TZD cell cycle leads to arrest at the G0/G1
phase and induced apoptosis, thus markedly suppressing pro-
liferation (Hirase et al., 1999). In addition, again in a myelo-
cytic cell leukemic line, signiﬁcant apoptosis induction with
BAX up-regulation of troglitazone and 15-deoxy-D12,14 –
prostaglandin J2 and down-regulation of Bcl-2 and survival
were also demonstrated (Liu et al., 2005).
Interestingly, PPARc was shown to inhibit initiation of
translation by inhibiting eukaryotic initiation factor-2 with
phosphorylation at high concentrations independent of its li-
gand-mediated activation (Palakurthi et al., 2001).
Complete remission can be achieved in 90% of the patients
with acute promyelocytic leukemia with ATRA treatment
(Sanz et al., 2009). In ATRA-resistant patients and those with
relapsing disease, however, use of arsenic trioxide and histone
deacetylase inhibitors in addition to PPARc agonists seems to
be a treatment choice. Inhibition of PPARc activity appears to
contribute to cessation of differentiation in APL pathophysiol-
ogy and, on the basis of this information, one may suggest that
PPARc activation with ligands results in differentiation of
APL cells.
Glitazones were described by Isseman and Green in 1990 as
molecules leading to gene transcription from nuclear receptors
and resulting in peroxisome proliferation (Isseman and Green,
1990). The present study investigated whether rosiglitazone
maleate, a synthetic ligand of PPARc, was cytotoxic for HL-
60, a myelocytic leukemic cell line. IC50 dose was at the
75 lM concentration level. As a PPARc agonist, rosiglitazone
maleate was preferred since it has the highest binding afﬁnity
to the PPARc receptor, i.e. lowest IC50, dose among other glit-
azones. PPARc receptor binding afﬁnity for rosiglitazone is
ten times that of pioglitazone and 100 times that of troglitaz-
one (Goldstein, 2002).
In previous studies with rosiglitazone maleate on the HL-60
cell line, the IC50 dose was not established and experiments
were terminated at lower concentrations (Konopleva et al.,
2004). Our experiments yielded an IC50 dose at higher concen-
trations compared to those described in the literature. Whether
cells differentiate or undergo apoptosis will be established as
20 S. Cetinkalp et al.the next step. This study obtained results which can provide
guidance for future studies. This will enable a signiﬁcant pro-
gress in the treatment of acute leukemia. Whether the PPARy
agonist rosiglitazone maleate may provide additive effects in
refractory or relapsing cases of acute leukemia may be set as
an objective for the future studies.
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